Literature DB >> 20011999

[Specific immunotherapy with depigmented allergoids].

L Klimek1, C Thorn, O Pfaar.   

Abstract

Specific immunotherapy is the only available causative treatment for IgE-mediated allergic conditions. The state of the art is treatment via the subcutaneous route with crude extracts in a water solution, with physically linked (semidepot) extracts or chemically modified semidepot extracts (allergoids). A relatively new purification method combines depigmentation followed by polymerization with glutaraldehyde. This modification results in increased tolerance with a reduction in both local and systemic adverse effects. As controlled clinical trials have shown, the effectiveness is comparable to that of specific immunotherapy with crude allergen extracts. Recent data suggest that the modified polymerized allergoids allow a safe rush titration in a few days or even in 1 day (ultra-rush titration).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20011999     DOI: 10.1007/s00106-009-2006-0

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  23 in total

Review 1.  Allergic rhinitis and its impact on asthma.

Authors:  J Bousquet; P Van Cauwenberge; N Khaltaev
Journal:  J Allergy Clin Immunol       Date:  2001-11       Impact factor: 10.793

2.  Clinical effects of specific immunotherapy: a two-year double-blind, placebo-controlled study with a one year follow-up.

Authors:  D Dokic; J Schnitker; A Narkus; O Cromwell; E Frank
Journal:  Prilozi       Date:  2005-12

3.  Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts.

Authors:  M Casanovas; R Martín; C Jiménez; R Caballero; E Fernández-Caldas
Journal:  Int Arch Allergy Immunol       Date:  2005-12-22       Impact factor: 2.749

4.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

Authors:  Christian Möller; Sten Dreborg; Hosne A Ferdousi; Susanne Halken; Arne Høst; Lars Jacobsen; Antti Koivikko; Dieter Y Koller; Bodo Niggemann; Lene A Norberg; Radvan Urbanek; Erkka Valovirta; Ulrich Wahn
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

5.  Efficacy and safety of specific immunotherapy with a modified mite extract.

Authors:  M Branco Ferreira; A Spínola Santos; M C Pereira Santos; M L Palma Carlos; M A Pereira Barbosa; A G Palma Carlos
Journal:  Allergol Immunopathol (Madr)       Date:  2005 Mar-Apr       Impact factor: 1.667

6.  Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life.

Authors:  E Alvarez-Cuesta; E Aragoneses-Gilsanz; C Martín-Garcia; P Berges-Gimeno; E Gonzalez-Mancebo; J Cuesta-Herranz
Journal:  Clin Exp Allergy       Date:  2005-05       Impact factor: 5.018

7.  Clinical efficacy and safety of a depigmented and glutaraldehyde polymerized therapeutic vaccine of Parietaria judaica.

Authors:  J García-Sellés; A Pascual; E Funes; J A Pagán; J-D López; J M Negro; J Hernández
Journal:  Allergol Immunopathol (Madr)       Date:  2003 Mar-Apr       Impact factor: 1.667

8.  Immunotherapy with a depigmented, polymerized vaccine of Olea europaea pollen allergens. Significantly reduces specific bronchial and skin test reactivity in sensitized patients after one year of treatment.

Authors:  F Guerra; J C Daza; E Almeda
Journal:  J Investig Allergol Clin Immunol       Date:  2003       Impact factor: 4.333

9.  Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study.

Authors:  C Bussmann; L Maintz; J Hart; J-P Allam; S Vrtala; K-W Chen; T Bieber; W R Thomas; R Valenta; T Zuberbier; A Sager; N Novak
Journal:  Clin Exp Allergy       Date:  2007-09       Impact factor: 5.018

10.  Significant improvement in symptoms, skin test, and specific bronchial reactivity after 6 months of treatment with a depigmented, polymerized extract of Dermatophagoides pteronyssinus and D. farinae.

Authors:  A Ferrer; J García-Sellés
Journal:  J Investig Allergol Clin Immunol       Date:  2003       Impact factor: 4.333

View more
  2 in total

1.  [Immunotherapy of allergic rhinitis without allergens? : new options for immunomodulation by vaccination with virus-like particles and CpG motifs].

Authors:  L Klimek; J Willers; P Schendzielorz; T M Kündig; G Senti
Journal:  HNO       Date:  2013-10       Impact factor: 1.284

Review 2.  Allergen Immunotherapy: Current and Future Trends.

Authors:  Gandhi F Pavón-Romero; Maria Itzel Parra-Vargas; Fernando Ramírez-Jiménez; Esmeralda Melgoza-Ruiz; Nancy H Serrano-Pérez; Luis M Teran
Journal:  Cells       Date:  2022-01-08       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.